IRMD at a glance
IRADIMED CORP (IRMD, SEC CIK 1325618) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on August 18, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), IRADIMED CORP (IRMD) reported revenue of $83.8 million (up 14.4% from FY2024) and net income of $22.5 million. Diluted EPS was $1.75.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding IRADIMED CORP (IRMD) shares worth $312.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ALLEN MONTY K on September 3, 2026 of 1,014 shares at $86.44 per share.
- In the last 90 days, IRMD insiders reported 0 open-market purchases ($0) and 2 open-market sales ($123K) on Form 4, a net sale of $123K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $83.8M
- +14.4% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$123K
- 13F holders
- 26 funds
- $312.3M · −5 vs prior quarter
- Latest 8-K
- Aug 18, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development and sale of MRI compatible medical devices, notably IV infusion pumps and patient vital signs monitors for safe MRI environment use
- New product emphasis: MRidium 3870 MRI Compatible IV Infusion Pump System launched in 2025 with Remote Display Unit for control from MRI control room
- Strategic shift: Discontinuation of older 3860+ infusion pump in 2026, focusing on new 3870 system; expanded intra-hospital use targeting ICU, ER, and critical care units
- Quantitative metric: 29 U.S. direct sales reps as of Dec 31, 2025; approximately 13,098 pump system channels and 3,397 vital signs monitors sold cumulatively
- Noteworthy fact: 2025 first commercial shipment of MRidium 3870; only known non-magnetic MRI compatible IV infusion pump operating up to 15,000 gauss magnetic field
Risk Factors
- FDA regulatory risk: potential refusal or revocation of 510(k) clearances affecting MRidium infusion pumps and 3880 patient monitors
- Geopolitical risk: supply chain disruption from tariffs, trade restrictions, and political instability impacting sourcing of proprietary raw materials
- Operational risk: single manufacturing facility in Orlando, Florida vulnerable to hurricanes or natural disasters disrupting production and shipments
- Competitive risk: mature market for 3880 patient monitoring system with competitors offering lower prices threatening revenue and margins
- Key-person risk: heavy dependence on founder and CEO Roger Susi with no guaranteed succession plan in place
Management Discussion & Analysis
- Revenue $83.8M in 2025, up 14.4% YoY from $73.2M in 2024, driven by U.S. sales +$10.0M (16.4%) and international sales +$0.6M (4.8%)
- Operating margin 31.2% in 2025 vs 30.0% in 2024; gross profit margin stable at 77% both years
- Best segment: MRI Compatible IV Infusion Pump Systems revenue $31.6M (+18.9%), worst: Services and other $3.9M (-4.1%)
- Cash from operations $24.9M in 2025 vs $25.6M in 2024; capex $8.4M primarily for new facility; financing outflows $17.6M, increased dividend payments and stock unit settlements
- Management confident liquidity sufficient for 12+ months; plans to monitor capital needs, potential financing, and invest in R&D, marketing, and possible acquisitions
AI summary of the IRMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes in risk factors from the 2025 Annual Report
- Carried-forward business risks remain applicable, including potential unknown or currently immaterial risks becoming material
- No new regulatory, legal, compliance, operational, competitive, market, or financial risk identified this quarter
AI summary of the IRMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued July 31, 2026
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, announced July 31, 2026
- Press release furnished as Exhibit 99.1, containing the financial results and management disclosures
Item 5.07: Submission of Matters to a Vote of Security Holders
- All five director nominees elected, preserving board continuity through the next annual meeting
- James Hawkins received weakest support, with 2,366,134 votes withheld, signaling notable shareholder concern
AI summaries of IRMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IRMD
Don't miss the next IRMD filing
- Alerts as it files. A push when IRMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IRMD, by share count.
- Ask anything. An AI agent that reads every IRMD filing and answers with sources.
IRMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| KIANI JOE E | M | Sep 23, 2026 | 698 | - |
| KIANI JOE E | M | Sep 23, 2026 | 698 | - |
| ALLEN MONTY K | Sell | Sep 3, 2026 | 1,014 | $86.44 |
| ALLEN MONTY K | Sell | Sep 3, 2026 | 405 | $86.35 |
| GLENN JOHN | M | Jun 20, 2026 | 5,796 | - |
| GLENN JOHN | F | Jun 20, 2026 | 2,319 | $92.20 |
| GLENN JOHN | M | Jun 20, 2026 | 5,796 | - |
| Scharen-Guivel Hilda Frederique | Sell | Jun 4, 2026 | 1,766 | $95.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $73.2M | $83.8M |
| Gross Profit | - | $56.3M | $64.3M |
| Operating Income | - | $22.0M | $26.1M |
| Net Income | - | $19.2M | $22.5M |
| Gross Margin | - | 76.9% | 76.7% |
| Op. Margin | - | 30.0% | 31.2% |
| Net Margin | - | 26.3% | 26.8% |
| Balance Sheet | |||
| Total Assets | $92.2M | $98.3M | $108.8M |
| Equity | $71.4M | $86.8M | $94.6M |
| ROE | - | 22.2% | 23.8% |
| Per Share | |||
| EPS | - | $1.50 | $1.75 |
| Cash Flow | |||
| Operating CF | - | $25.6M | $24.9M |
| CapEx | - | $8.0M | $7.8M |
Source: XBRL data in IRADIMED CORP (IRMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate IRMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $312.3M |
| Q1 2026 | 31 | $327.8M |
| Q4 2025 | 26 | $325.9M |
| Q3 2025 | 28 | $240.6M |
| Q2 2025 | 27 | $190.9M |
| Q1 2025 | 23 | $116.0M |
| Q4 2024 | 21 | $103.4M |
| Q3 2024 | 15 | $65.1M |
- Two Sigma Investments+17.2K (+10%)
- State Street Corp+17.0K (+8%)
- Wells Fargo & Co+16.4K (+66%)
- Goldman Sachs Group+16.2K (+8%)
- Northern Trust+10.0K (+8%)
- Renaissance Technologies LLC−46.3K (-11%)
- Morgan Stanley−23.8K (-16%)
- Prudential Financial−18.7K (-52%)
- JPMorgan Chase & Co−17.6K (-60%)
- Invesco Ltd−11.3K (-60%)
- Millennium Management−40.5K
- Citadel Advisors LLC−32.5K
- D.E. Shaw & Co−18.0K
- Raymond James Financial−13.6K
- Ameriprise Financial−7.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 197 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IRMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 28, 2026 | - | - | |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 8-K | May 1, 2026 | - | Analysis | - |
| 10-Q | May 1, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 15, 2026 | - | - | - |
| 4 | Apr 7, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 4 | Mar 18, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
IRMD SEC filings: frequently asked questions
Are IRMD insiders buying or selling?
In the last 90 days, IRADIMED CORP (IRMD) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $122,622 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold IRMD stock?
As of June 30, 2026, the largest IRADIMED CORP (IRMD) holders among the 13F filers tracked by SignalX were BlackRock ($92.5 million), Renaissance Technologies LLC ($37.7 million), Vanguard Capital Management LLC ($34.9 million), Dimensional Fund Advisors ($21.9 million), State Street Corp ($21.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IRMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), IRADIMED CORP (IRMD) reported revenue of $83.8 million (up 14.4% from FY2024) and net income of $22.5 million. Diluted EPS was $1.75. The figures come from the XBRL data in the 10-K.
What are the main risks in IRMD's latest 10-K?
In the 10-K filed March 6, 2026, IRADIMED CORP (IRMD) flagged: FDA regulatory risk: potential refusal or revocation of 510(k) clearances affecting MRidium infusion pumps and 3880 patient monitors. Geopolitical risk: supply chain disruption from tariffs, trade restrictions, and political instability impacting sourcing of proprietary raw materials. (AI summary of the Risk Factors section.)
What did IRMD report in its latest 8-K?
IRADIMED CORP (IRMD) filed an 8-K on August 18, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026.
What are the latest IRMD SEC filings?
IRADIMED CORP (IRMD) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on August 18, 2026 and a Form 4 insider filing on September 25, 2026.
What is IRMD's SEC CIK number?
IRADIMED CORP (IRMD)'s SEC Central Index Key (CIK) is 1325618. EDGAR lists every IRMD filing under that number.
Ask anything about IRMD
The research agent reads IRMD's filings, financials, insider trades and 13F holders, then answers with sources.